Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Blood Advances|January 10, 2024
Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AMLJacqueline S Garcia, Haesook T Kim, H Moses Murdock, et al.
Blood|March 14, 2022
Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AMLH Moses Murdock, Haesook T Kim, Nathan Denlinger, et al.
Blood Advances|October 6, 2021
Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and activeJacqueline S Garcia, Haesook T Kim, H Moses Murdock, et al.
Blood Advances|December 5, 2025
Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor risk MDS/AMLJacqueline S Garcia, Haesook T Kim, H Moses Murdock, et al.
Blood Advances|February 24, 2026
No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapseH Moses Murdock, Haesook T Kim, Katie Maurer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2021
Donor Clonal Hematopoiesis and Recipient Outcomes After TransplantationChristopher J Gibson, Haesook T Kim, Lin Zhao, et al.
Blood Cancer Discovery|January 11, 2022
BCOR and BCORL1 Mutations Drive Epigenetic Reprogramming and Oncogenic Signaling by Unlinking PRC1.1 from Target GenesEva J Schaefer, Helen C Wang, Hannah Q Karp, et al.
Blood Advances|October 31, 2025
No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapseH Moses Murdock, Haesook T Kim, Katie Maurer, et al.
Pageof 2